A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks of tubular aggregate myopathy by Cordero-Sanchez, C. et al.
RESEARCH ARTICLE
A luminal EF-hand mutation in STIM1 in mice causes the clinical
hallmarks of tubular aggregate myopathy
Celia Cordero-Sanchez1,‡, Beatrice Riva1,‡, Simone Reano2,‡, Nausicaa Clemente2, Ivan Zaggia2,
Federico A. Ruffinatti1, Alberto Potenzieri1,*, Tracey Pirali1, Salvatore Raffa3, Sabina Sangaletti4,
Mario P. Colombo4, Alessandra Bertoni2, Matteo Garibaldi5, Nicoletta Filigheddu2,‡,§,¶ and
Armando A. Genazzani1,‡,§,¶
ABSTRACT
STIM and ORAI proteins play a fundamental role in calcium signaling,
allowing for calcium influx through the plasma membrane upon
depletion of intracellular stores, in a process known as store-operated
Ca2+ entry. Point mutations that lead to gain-of-function activity of either
STIM1 or ORAI1 are responsible for a cluster of ultra-rare syndromes
characterized by motor disturbances and platelet dysfunction. The
prevalence of these disorders is at present unknown. In this study, we
describe the generation and characterization of a knock-in mouse
model (KI-STIM1I115F) that bears a clinically relevant mutation located
inoneof the two calcium-sensingEF-handmotifs ofSTIM1. Themouse
colony is viable and fertile. Myotubes from these mice show an
increased store-operated Ca2+ entry, as predicted. This most likely
causes the dystrophic muscle phenotype observed, which worsens
with age. Such histological features are not accompanied by a
significant increase in creatine kinase. However, animals have
significantly worse performance in rotarod and treadmill tests,
showing increased susceptibility to fatigue, in analogy to the human
disease. The mice also show increased bleeding time and
thrombocytopenia, as well as an unexpected defect in the myeloid
lineage and in natural killer cells. The present model, together with
recently describedmodels bearing theR304Wmutation (located on the
coiled-coil domain in the cytosolic side of STIM1), represents an ideal
platform to characterize the disorder and test therapeutic strategies for
patients with STIM1 mutations, currently without therapeutic solutions.
This article has an associated First Person interview with Celia
Cordero-Sanchez, co-first author of the paper.
KEY WORDS: STIM1, Calcium signaling, Mouse model, Rare
disease, Store-operated calcium entry
INTRODUCTION
High concentrations of calcium ions are present in intracellular
organelles [in particular in the endoplasmic reticulum (ER)/
sarcoplasmic reticulum (SR)], and the opening of Ca2+ channels
located on these membranes (e.g. ryanodine receptors, inositol
1,4,5-trisphosphate receptors) allows this ion to flux out of the
deposit and elicit cellular signals. A crosstalk mechanism between
the ER and the plasma membrane exists that allows for the refilling
of the depleted organelles (Putney, 2011). This crosstalk is known
as store-operated Ca2+ entry (SOCE). The principal components of
SOCE are a Ca2+ sensor on the ER membrane (STIM protein) and a
plasma membrane Ca2+ channel (ORAI protein) (Lacruz and Feske,
2015; Berna-Erro et al., 2012). STIM proteins are single-span
membrane proteins, highly conserved across species. Two members
of the family have been described, STIM1 and STIM2, of which the
former appears more expressed. ORAI channels reside on the
plasma membrane, and three members of the family (ORAI1,
ORAI2 and ORAI3) have been described, with ORAI1 being the
most abundant. Importantly, other crucial proteins participate in the
SOCE process, including transient receptor potential canonical
(TRPC) channels (Ong and Ambudkar, 2015).
Genetic defects of STIM and ORAI proteins have been described
that give rise to loss-of-function and gain-of-function genetic
disorders (Lacruz and Feske, 2015; Böhm and Laporte, 2018;
Feske, 2010). Gain-of-function disorders primarily affect skeletal
muscles and platelets, although other organs also seem to be
affected. Given the rarity of the disorders, compared to other
myopathies, their prevalence is currently unknown; they have not
been tackled systematically in the clinic, and disease registries are
not available at present. Both STIM1 and ORAI1 mutations are
linked to three separate, but overlapping, disorders: tubular
aggregate myopathy (TAM), Stormorken syndrome and York
platelet syndrome. TAM is characterized by variable combinations
of myalgias, cramps and muscle stiffness, with or without weakness
with a predominantly proximal distribution (Böhm et al., 2014), and
by the presence of tubular aggregates, which are regular arrays of
tubules derived from the SR (Schiaffino, 2012). Stormorken
syndrome (Stormorken et al., 1995) is variably characterized by
myopathic signs, mild bleeding tendency due to platelet
dysfunction, thrombocytopenia, anemia, asplenia, congenital
miosis, ichthyosis, headache and recurrent stroke-like episodes
(Nesin et al., 2014; Misceo et al., 2014; Noury et al., 2017). In York
platelet syndrome, blood dyscrasias is the main phenotype
(Markello et al., 2015). Fig. 1A illustrates the mutations reportedReceived 21 June 2019; Accepted 24 October 2019
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so far. Briefly, mutations of STIM1 mostly reside in the EF-hand
Ca2+-binding motifs, most likely modifying the affinity for Ca2+
ions of the protein, with few exceptions located on the cytosolic
coiled-coil domains. The R304W mutation has recently been
shown to affect the dimerization and resting state of STIM1
(Fahrner et al., 2018). A second substitution at the same position
(R304Q; Harris et al., 2015) and a deletion on the third coiled-coil
domain have also been reported (I484R fs*21; Okuma et al., 2016).
Fig. 1. See next page for legend.
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The mutations of ORAI1 are located in the transmembrane domains
in positions that might lead to the assumption that the resultant
amino acids participate in the channel lining.
There are three reported mouse models bearing gain-of-function
mutations of STIM1. The first model originated from a mutation
of STIM1 (STIM1Sax; D84G), generated via random chemical
mutagenesis, located in the intraluminal EF-hand domain.
STIM1Sax is characterized by severe thrombocytopenia, but no
muscular phenotype was reported (Grosse et al., 2007). Recently,
two groups have described mice bearing the R304W mutation,
which leads to Stormorken syndrome (Silva-Rojas et al., 2018;
Gamage et al., 2018). Both groups found bleeding disorders and a
muscular phenotype. Surprisingly, no models exist that investigate
and reproduce clinically relevant mutations located on the luminal
side of STIM1.
In this study, we have generated and characterized a knock-in
animal bearing a mutation in one of the two EF-hand motifs.
Heterozygous mice bearing the I115F mutation display important
histological and functional muscle dysfunctions associated with
thrombocytopenia, and unexpected hematological defects related to
the myeloid lineage and natural killer (NK) cells.
RESULTS
Development of the KI-STIM1I115F mouse colony
The knock-in (KI) STIM1I115F mouse model was generated by
homologous recombination by PolyGene Transgenetics. Details are
provided in the Materials and Methods section.
Both male and female mice are fertile. Given that the disorder is a
dominant gain-of-function, it was decided to routinely breed wild-
type (WT) and heterozygous (KI-STIM1I115F) mice. The genotype
ratio of born pups was 120:118 and did not significantly deviate
from the expected Mendelian ratio of 1:1. Average litter size was
7.2+0.5 (n=36 litters). Anecdotally, two matings were attempted
between heterozygous animals. One of the matings did not result in
a litter, while the other resulted in two pups (one WT and one
heterozygous). Given that characterization of homozygosity was not
an aim, we did not analyze whether this was a result of embryonic
lethality, and we did not breed between heterozygous animals
further.
The Kaplan–Meier of survival shows that there are no signs of
early mortality, and KI-STIM1I115F mice survive over 1 year, like
WT animals (Fig. 1B). Animals were not bred for longer, and
therefore data are not sufficient to define the median survival of
animals and whether the mutation leads to a decreased lifespan.
With age, KI-STIM1I115F mice may display an arched back that
worsens with age, may limp and show tremors, and manifest an
instantaneous post-mortem rigidity.
On visual inspection, KI-STIM1I115F mice are smaller than WT
mice, and this rendered blinding difficult for behavioral tests. The
size difference (Fig. 1C) could be better appreciated whenmicewere
weighed, and a significant difference between KI-STIM1I115F and
WT could be observed at all time points evaluated (1, 3, 6,
12 months), when net weight or body weight adjusted for length
(anus-nose) were considered (Fig. 1D). Animal length was not
significantly different between KI-STIM1I115F and WT mice, also
when normalized for tibial length.
At necropsy, the weights of the heart and spleen from KI-
STIM1I115F animals were determined and were not statistically
different from those of WT (Fig. 1E,F). However, when body
weight was taken into account, a statistically significant increase in
heart size was evident at 12 months, while an increased spleen/body
weight ratio was already observable at 3 months.
We also proceeded to analyze whether males (50 WT and 58 KI-
STIM1I115F) and females (71 WT and 59 KI-STIM1I115F) differed.
We did not find any significant differences between the sexes
regarding survival at 1 year, body weight, animal length, heart size
and spleen size (Figs S1 and S2), thereby suggesting that there is not
a sex difference in penetrance of the disease.
Myotubes from the KI-STIM1I115F mouse colony retain
increased SOCE
We next examined whether myotubes from KI-STIM1I115F mice
retained the fundamental cellular characteristic of increased Ca2+
entry upon store depletion (SOCE). Myotubes were generated from
four animals in each condition. We also analyzed whether SOCE in
WTmyotubes was modified during the lifespan of these animals. To
do this, we employed a classical protocol for Ca2+ entry, in which
stores are depleted with 2,5-t-butylhydroquinone (tBHQ) in a Ca2+-
free buffer, and, after 10 min, cells are perfused in a Ca2+-containing
solution (2 mM).
As can be observed in Fig. 2, myotubes from KI-STIM1I115F
display a significantly augmented SOCE compared to WT at
1 month. The increased SOCE was retained throughout all time
points examined (1, 3, 6, and 12 months). Interestingly, SOCE
from WT myotubes appeared to be higher in younger animals
(1 month) and decreased at the subsequent time points. It is also
interesting to note that, in myotubes from mice at 6 and 12 months,
there was a reduced sustained entry compared to the earlier
time points.
We next analyzed the Ca2+ entry pattern and found that slope,
peak Ca2+ entry and area under the curve differed between KI-
STIM1I115F and WT mice, except at 1 month, when the slope
appeared similar (Fig. 2; Fig. S3). We also investigated whether we
could observe any spontaneous oscillations in intracellular Ca2+, or
whether there were changes in basal Ca2+ between WT and KI-
STIM1I115F mice. No difference in basal Ca2+ between the two
groups was observed when considering the same age group.
Furthermore, analysis for 20 min of ∼50 cells per time point did not
yield any oscillations, in any of the two strains.
We evaluated whether Ca2+ entry genes (Trpc1, Trpc2, Trpc3,
Trpc4, Trpc5,Orai1,Orai2,Orai3, Stim1 and Stim2) were modified
Fig. 1. Characterization of KI-STIM1I115F mice multi-systemic phenotype.
(A) Known point mutations leading to gain-of-function phenotypes in humans.
ER, endoplasmic reticulum; PM, plasma membrane. (B) Kaplan–Meier for
survival of WT and KI-I115F. Numbers below the graph indicate numbers at
risk, i.e. the number of true observations made to estimate survival. (C) Body
weight at 1 (WT n=6, KI-I115F n=5), 3 (WT n=6, KI-I115F n=6), 6 (WT n=4,
KI-I115F n=4) and 12 (WT n=8, KI-I115F n=8) months, shown as ratio to
anal-nose length (ANL) on the left axis and net body weight on the right axis.
Scatter plots and histograms show the means±s.e.m. of the indicated number
of mice. Unpaired Student’s t-test with Welch’s correction. *P≤0.0386,
**P=0.0068, ****P<10−4 versus WT. (D) Body length at 1 (WT n=6, KI-I115F
n=5), 3 (WT n=6, KI-I115F n=6), 6 (WT n=4, KI-I115F n=4) and 12 (WT n=8,
KI-I115F n=8) months, shown as ratio to tibial length on the left axis and net
body length on the right axis. Scatter plots and histograms show the means
±s.e.m. of the indicated number of mice. Unpaired Student’s t-test withWelch’s
correction. (E) Heart weight at 1 (WT n=6, KI-I115F n=5), 3 (WT n=6, KI-I115F
n=6), 6 (WT n=4, KI-I115F n=4) and 12 (WT n=8, KI-I115F n=8)months, shown
as ratio to body weight on the left axis and net weight on the right axis. Graph
shows median and IQR of heart weight/body weight, or heart net weight.
Mann–Whitney U-test. **P=0.003 versus WT. (F) Spleen weight at 1 (WT n=6,
KI-I115F n=5), 3 (WT n=6, KI-I115F n=6), 6 (WT n=4, KI-I115F n=4) and 12
(WT n=8, KI-I115F n=8) months, shown as ratio to body weight on the left axis
and net weight on the right axis. Graph shows median and IQR of spleen
weight/body weight, or spleen net weight. Mann–Whitney U-test. *P≤0.026,
**P=0.0037 versus WT.
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in their expression between the two groups at 1, 3, 6, and 12 months
(Fig. S4). No major differences were observed by quantitative real-
time PCR (qRT-PCR). Indeed, we did not observe a compensatory
decrease in Stim1 mRNA expression. Although we did observe
some minor, albeit statistically significant, differences at different
time points, these were not consistent and are most likely a result of
bias for multiple testings.
Muscles in KI-STIM1I115F mice present significant
histological and functional alterations
We then analyzed muscle weight in animals of different ages. As
shown in Fig. 3A, the gastrocnemius and quadriceps muscles in KI-
STIM1I115F animals weigh significantly less compared to in WT
animals at 3 months (no change was observed at 1 month; data not
shown), and all muscles evaluated, except for the soleus, weigh less
in KI-STIM1I115F than in WT animals at 12 months. Similar trends
were observed when a subanalysis was performed betweenmale and
female animals (Fig. S5). The paradoxical finding of the increased
weight of the soleus at 6 and 12 months parallels the report on
R304W mice by Silva-Rojas et al. (2018). Cross-sectional area
(CSA) analysis of the tibialis anterior (TA) fibers shows a higher
frequency of smaller areas in KI-STIM1I115F animals compared to
WT, and this worsens with age (Fig. 3B). A similar trend was
observed in the quadriceps and extensor digitorum longus, but not
in the soleus (Fig. 3C), in accord with the data obtained frommuscle
weight analyses (Fig. 3A).
Histological sections of the quadriceps and upper biceps were
obtained to evaluate muscle morphology. Hematoxylin-Eosin,
Masson Trichrome and Gomori Trichrome stainings were
performed (Fig. 4A,B). A myopathic process was evident from
1 month and worsened with age. It was characterized by marked
fiber size variability, necrosis and regeneration with newly formed
myofibers with central nuclei, and increased connective tissue.
Interestingly, in the quadriceps and upper biceps of 6-month-old
animals, endomysial inflammatory infiltrates as well as cytoplasmic
fuscinophilic areas in Gomori Trichrome staining were observed
(Fig. 4B). In electron microscopy of 6-month-old animals
(quadriceps and upper biceps), enlarged mitochondria with
abnormal morphology were observed (for example, hypertrophic
with loss of the mitochondrial crest; Fig. 4C, left column), which at
Fig. 2. SOCE alterations in myotubes. Evaluation of SOCE by calcium imaging in myotubes from WT and KI-I115F at (A) 1, (B) 3, (C) 6 and (D) 12 months
of age. Traces are the average of at least 180 myotubes from 6-well plates on two different experimental days. At all time points, myotubes from four
animals (two males, two females) for each condition were used.
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times formed circular structures (Fig. 4C, top left). Some
mitochondria were located in a subplasmallemal position
(Fig. 4C, middle and bottom left), which might explain some
features observed in Gomori staining (e.g. Fig. 4B, bottom row).
Inside the circular structures formed by mitochondria, no
sarcomeric structures were observed, although pseudo-aggregate
structures were at times visible (Fig. 4C, middle and bottom right),
and they resembled, in part, the characteristics of the human
disorders, but were disorganized and chaotic. However, no true
tubular aggregates were observed at either 6 or 12 months, and these
pseudo-aggregates were not observable in 12-month-old animals.
These features were accompanied by a partial disorganization of
myofibrils (Fig. 4D). Subsequently, we proceeded to analyze
myosin in fibers. The frequency distribution of type IIa fibers
Fig. 3. Reduced muscle growth and damage in KI-STIM1I115F mice. (A) Muscle weight in WT and KI-I115F mice at 3 (WT n=6, KI-I115F n=6), 6 (WT n=4,
KI-I115F n=4) and 12 (WT n=8, KI-I115F n=8) months. (Gastro, gastrocnemius; TA, tibialis anterior; Quad, quadriceps; EDL, extensor digitorum longus).
Histograms show median and IQR of muscle weight. Mann–Whitney U-test. *P≤0.0303, **P≤0.0022, ***P≤0.0003 versus WT. (B) Cross-sectional area (CSA)
frequency distribution of fibers in TA at 3 (WT n=6, KI-I115F n=6), 6 (WT n=4, KI-I115F n=4) and 12 (WT n=6, KI-I115F n=6) months. (C) CSA frequency
distribution of fibers in quadriceps (Quad, top; WT n=4, KI-I115F n=3), extensor digitorum longus (EDL, middle; WT n=3, KI-I115F n=4) and soleus (bottom; WT
n=3, KI-I115F n=3) at 6 months.
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Fig. 4. Muscle histology of KI-STIM1I115F mice. (A) Representative images of Hematoxylin-Eosin (top row), Masson Trichrome (middle row) and Gomori
Trichrome (bottom row) staining of the quadriceps at 6 months of age. Green arrows indicate fibrotic tissue and inflammatory cell infiltration; yellow arrows indicate
necrotic fibers. (B) Representative images of Gomori Trichrome staining in the quadriceps (left column) and upper biceps (right column) from 6-month-old
KI-I115F mice that show cytoplasmic fuscinophilic areas (top andmiddle rows) and inflammatory infiltrates (bottom row). (C) Representative electron microscopic
images of the quadriceps of 6-month-old KI-I115F mice, showing pseudo-tubular aggregates (right column) and mitochondrial alterations (left column).
(D) Representative electron microscopic images of the quadriceps of 6-month-old KI-I115F mice, showing myofibrillar dysorganization. (E) Creatine kinase (CK)
plasma concentrations. Mean±s.e.m. at 3 (WT n=16, KI-I115F n=15), 6 (WT n=17, KI-I115F n=11) and 12 (WT n= 20, KI-I115F n=15) months. *P=0.011
versus WT.
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was increased in the quadriceps, whereas no differences were
observed in the extensor digitorum longus. In the soleus, both
type IIa and type I fibers were decreased in KI-STIM1I115F
compared to WT animals, but this was paralleled by a marked
increase in fibers that were negative for both type IIa and type I
myosin (Fig. S6).
Despite the marked histopathological alterations in muscle
tissue, only small differences in serological creatine kinase (CK)
levels were observed between KI-STIM1I115F and WT during the
entire lifespan (Fig. 4E). A significant variability in CK levels
was observed, presumably due to the low levels detected. Similar
trends were observable in a subanalysis of male and female animals
(Fig. S7).
Finally, we analyzed the motor and strength performances of the
animals. KI-STIM1I115F mice performed similarly to WT mice, both
in the grip strength and hanging test, although a reduced performance
was evident at around 2-3 months, which then recovered to levels
comparable toWT (Fig. 5A,B). In contrast, when animals were tested
on the rotarod or the treadmill, an underperformance of KI-
STIM1I115F with respect to WT was already evident at 3 months
(the earliest age at which these tests can be performed reproducibly)
and was maintained up to 1 year (Fig. 5C,D).
KI-STIM1I115F mice display hematological defects
We next proceeded to determine platelet count in animals at 3, 6 and
12 months. As shown in Fig. 6A, significant thrombocytopenia was
evident in KI-STIM1I115F mice of all ages. This reduced number of
platelets was reconciled with an increased bleeding time, which was
evaluated via the tail test (Fig. 6B). Of the 19 KI-STIM1I115F mice
tested, only two stopped bleeding within 10 min of the incision,
compared to 20 out of 23 in the WT animals.
To gain an insight into other hematological dyscrasias, we next
evaluated the frequency of circulating B and T lymphocytes in WT
or KI-STIM1I115F mice at 6 months of age. As shown in Fig. 6C
(top row), we could not detect any difference in the frequency of T
cells (CD45+CD3+cells), B cells (CD45+B220+cells) and CD11b+
cells (CD45+Cd11b+) between KI-STIM1I115F and WT. We also
evaluated the myeloid populations, and found that KI-STIM1I115F
mice displayed similar levels of total granulocytes
(CD45+Cd11b+Ly6G+) compared to WT (Fig. 6C, bottom row).
In contrast, KI-STIM1I115F showed impairment of the monocyte
subsets. As shown in Fig. 6C (bottom row), the number of Ly6Chigh
monocytes (CD45+Cd11b+Ly6G−Ly6Chigh cells) was increased in
KI-STIM1I115F mice, with a marked reduction in the levels
of Ly6Clow monocytes (CD45+Cd11b+Ly6G−Ly6Clowcells),
Fig. 5. Characterization of muscular functionality of KI-STIM1I115F mice. (A) Grip strength performance at 1 (WT n=45, KI-I115F n=40), 2 (WT n=35,
KI-I115F n=27), 3 (WT n=39, KI-I115F n=34), 4 (WT n=34, KI-I115F n=30), 5 (WT n=34, KI-I115F n=25), 6 (WT n=19, KI-I115F n=14) and 12 (WT n=13, KI-I115F
n=12) months. Graph shows the means±s.e.m. of the falling score. Unpaired Student’s t-test with Welch’s correction. *P=0.02 versus WT. (B) Hanging test
performance at 1 (WT n=45, KI-I115F n=37), 2 (WT n=37, KI-I115F n=32), 3 (WT n=42, KI-I115F n=33), 4 (WT n=35, KI-I115F n=29), 5 (WT n=32, KI-I115F
n=26), 6 (WT n=17, KI-I115F n=14) and 12 (WT n=18, KI-I115F n=18) months. Graph shows the means±s.e.m. of the score (see Materials and Methods).
Unpaired Student’s t-test with Welch’s correction. *P=0.0312, **P=0.0064 versus WT. (C) Rotarod test performance at 3 (WT n=11, KI-I115F n=17), 6 (WT n=13,
KI-I115F n=10) and 12 (WT n=13, KI-I115F n=13) months. The 3-month data were analyzed by one-sample Student’s t-test KI-I115F versus 300 s. All WT mice
achieved the endpoint of the experiment (300 s). Graph shows the means±s.e.m. of the latency to fall in WT and KI-I115F. Unpaired Student’s t-test with Welch’s
correction. **P=0.0034 KI-I115F versus 300 s. **P=0.0096, ****P<10−4 versus WT. (D) Treadmill test performance at 3 (WT n=7, KI-I115F n=9), 6 (WT n=15,
KI-I115F n=15) and 12 (WT n=16, KI-I115F n=8) months. Graph shows the means±s.e.m. of the time to exhaustion. Unpaired Student’s t-test with Welch’s
correction. *P=0.0116, **P=0.0041, ****P<10−4 versus WT.
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compared to WT. These data demonstrate that KI-STIM1I115F mice
have a normal T and B subset, but suggest an alteration in monocyte
differentiation. Furthermore, to investigate the impact of the
mutation on the immune system, we quantified regulatory T
(Treg) (CD4+FOXp3+CD25+) and NK (CD3−CD11b−CD49b+)
cells in the spleen of WT and KI-STIM1I115F mice. As shown in
Fig. 6D, only the number of NK cells was significantly reduced
in KI-STIM1I115F compared to WT animals, suggesting a putative
role of the STIM1 p.I115F mutation in the differentiation/
maturation of NK cells (Abel et al., 2018). The gating strategies
of fluorescence-activated cell sorting (FACS) analyses are reported
in Fig. S8.
Fig. 6. Evaluation of hematological defects in
KI-STIM1I115F mice. (A) Platelet count at 3
(WT n=8, KI-I115F n=7), 6 (WT n=9, KI-I115F n=11)
and 12 (WT n=8, KI-I115F n=10) months. Histogram
shows the means±s.e.m. of the number of platelets
in WT and KI-I115F. Unpaired Student’s t-test with
Welch’s correction. ***P=0.0015, ****P<10−4 versus
WT. (B) Bleeding time at 3 (WT n=5, KI-I115F n=4),
6 (WT n=10, KI-I115F n=7) and 12 (WT n=8,
KI-I115F n=8) months. Scatter plots show bleeding
time. Unpaired Student’s t-test with Welch’s
correction. *P≤0.0256, **P=0.0064 versus WT. (C)




populations in blood from mice at 6 months
(WT n=11, KI-I115F n=17). Unpaired two-tailed
Student’s t-test was used for statistical analysis.
*P=0.0193, ****P<0.0001 versus WT. (D) CD3
(CD45+CD3+), Treg (CD4+Foxp3+CD25+) and NK
(CD3−CD11b−CD49b+) cells in spleen from mice at
6 months (WT n=6, KI-I115F n=8). Unpaired
two-tailed Student’s t-test was used for statistical
analysis. ***P=0.0002 versus WT.
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TAM, Stormorken syndrome and York platelet syndrome represent
a cluster of ultra-rare genetic diseases that can be attributed to
overactivation of SOCE, a fundamental mechanism that allows
calcium replenishment after ER store emptying. These disorders are
driven by mutations in one of two key proteins involved in SOCE
(STIM and ORAI). These mutations lead to gain-of-function
proteins, and the clinical hallmarks are muscle weakness and
platelet dysfunction. The two hallmarks may have variable
penetrance in each individual, also according to the mutation.
In the present study, we generated a mouse colony bearing the
I115F (c.343A>T) constitutive knock-in point mutation (KI-
STIM1I115F), on a C57Bl/6 background. This mutation is located
in one of the two luminal EF-hand Ca2+-binding motifs, and has
been associated in the clinic with TAM and York platelet syndrome
(Lacruz and Feske, 2015). Although a mouse bearing a mutation in
the EF-hand motifs (STIM1Sax; D84G) has been described, the
muscle phenotype was either not present or was not investigated
(Grosse et al., 2007), as only a severe thrombocytopenia was
reported. Two independent groups have reported the generation and
characterization of mouse colonies that bear the R304W mutation,
which is characteristic of TAM and Stormorken syndrome (Silva-
Rojas et al., 2018; Gamage et al., 2018). The R304W mutation is
located on the cytosolic domains of STIM1, and therefore our model
is perfectly complementary to that described earlier.
KI-STIM1I115F mice are fertile, breed well in heterozygosity
and ∼50% of newborns display the mutation. The Mendelian ratio
obtained when heterozygous animals were mated with WTwas 1:1,
which was as expected. This is partly in contrast to results reported
by Silva-Rojas et al. (2018) for STIM1R304W, as fewer than expected
heterozygous pups were observed.
KI-STIM1I115F mice are lighter than WT mice, which might
reconcile with the decreased muscle weight that is observed.
Importantly, this manifestation can be observed at 1 month of age,
making it a good surrogate early endpoint to investigate drugs in the
future. Similarly, platelet dysfunction can also be observed early,
providing a further early read-out.
KI-STIM1I115F mice showed a normal performance in the grip
strength and hanging tests. This somehow differs from the model
described by Silva-Rojas et al. (2018), in which STIM1R304W mice
showed impaired performance at 9 weeks (the only time assessed).
We found, instead, a strong impairment in both the rotarod
and treadmill tests, which also contrasts with observations by
Silva-Rojas et al. (2018) (at 9 weeks) and Gamage et al. (2018) (at
5-6 months). Our model, therefore, appears to show functional
deficits in tests that evaluate motor coordination (rotarod test) and
speed activity (treadmill test), suggesting a prevalent impairment in
actions that require running or sprinting, a deficit also reported
in TAM patients (Walter et al., 2015). The negative performance of
KI-STIM1I115F mice in the rotarod test is unlikely to be attributable
to balance impairment, as this is not supported by the hanging test
(a functional test that also requires coordination), demonstrating
muscle involvement but not a cerebellar deficit.
In line with the Ca2+ overload detected in myotubes from TAM
patients, in KI-STIM1I115F myotubes, we observed a SOCE
overactivation that was maintained during the entire lifespan,
unlike what was observed in WT mice. However, in contrast to
previous data reported in TAM patient myotubes (Garibaldi et al.,
2016), we did not observe any increase in basal calcium levels or
spontaneous oscillations in KI-STIM1I115F myotubes. This
observation at present has no explanation, although preliminary
evidence reveals that platelets from KI-STIM1I115F animals instead
show an increased basal Ca2+ level (C.C.-S., unpublished).
Histopathological findings in KI-STIM1I115F mice revealed a
progressive muscle degeneration. Muscle tissue showed histological
features consistent with a myopathic process, similar to those
observed in the other mice models (Silva-Rojas et al., 2018;
Gamage et al., 2018). Given the different times at which muscles
were evaluated in the different models, comparison of the severity of
the myopathy is not possible. In our model, at 12 months, muscles
showed a severe myopathic process. When evaluating different
muscles at 6 months, we found mitochondrial alterations and the
presence of aggregates that, in part, may represent the counterpart of
the human hallmark, although they were not superimposable. It is
worth noting, therefore, that all three models lack true tubular
aggregates (Silva-Rojas et al., 2018; Gamage et al., 2018), although
the pseudo-aggregates observed in KI-STIM1I115F mice will require
more investigation in the future. Interestingly, we detected in some
mice abundant endomysial inflammatory infiltrates, a pathological
feature that has been reported in a mouse model overexpressing
STIM1 (Goonasekera et al., 2014). In KI-STIM1I115F, the
myopathic process was not paralleled by significant increases in
CK levels. Although an increasing trend was observed, the
variability, which might have been due to the technology used or
to true inter-individual variability, did not lead to consistent
statistical significance.
As reported in patients carrying the STIM1 p.I115F mutation, our
mouse model also displays a severe platelet dysfunction. At all time
points evaluated, we observed a marked reduction in platelet
number, which is likely to be linked to the increased bleeding time.
It has previously been reported in the STIM1Sax mouse that
thrombocytopenia is associated with increased basal calcium in
platelets, resulting in a pre-activation state (Grosse et al., 2007).
Such a mechanism would be compatible with our findings; indeed,
in preliminary experiments, we confirmed this increase in basal
Ca2+. Importantly, the two R304W models have contradictory
findings on platelets: whereas Silva-Rojas et al. (2018) found a
significantly decreased platelet number, Gamage et al. (2018) found
no differences in heterozygous animals and attributed this negative
finding to a compensatory reduction in STIM1 protein. The KI-
STIM1I115F model did not display compensatory mechanisms, at
least at the mRNA level.
Considering the crucial role of SOCE in the immune system
(Feske et al., 2010) and the involvement of STIM and ORAI loss-of-
function mutations in severe immunodeficiencies (Lacruz and
Feske, 2015), we investigated the impact of the STIMI115F mutation
on circulating T lymphocytes, B lymphocytes, neutrophils and
monocytes. In contrast to observations by Silva-Rojas et al. (2018),
in STIMR304W, we did not find impairment of T cells or a significant
increase in the levels of neutrophils, but found alterations in
monocyte subsets and in NK cells, which are worth exploring in
patients in the future.
To date, 12 point mutations have been reported on the
intraluminal EF-hand motifs and four mutations/deletions
described in the cytosolic coiled-coil domains of STIM1. Given
the extremely low frequency of these mutations, it is plausible that
only drugs that will be able to counteract most of these mutations
will find sufficient patients to treat in clinical trials and be approved.
In this respect, we believe the presence of complementary models
mimicking luminal and cytosolic mutations will increase the
likelihood of success for the development of effective drugs for
patients that are – at present – lacking therapeutic options.
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KI-STIM1I115F mouse model generation and animal care
The care and husbandry of animals were in conformity with the institutional
guidelines, in compliance with national and international laws and policies.
Mice were housed in ventilated cages in 22±1°Cmonitored rooms with 12 h
light/dark cycles, had access to food and water ad libitum, and were weaned
at 23 days by sex. The procedures were approved by the local animal-health
and ethical committee (Università del Piemonte Orientale) and authorized
by the national authority (Istituto Superiore di Sanità; authorization number
N. 194/2019-PR).
KI-STIM1I115F founders in a C57Bl/6N background were obtained from
PolyGene Transgenics (https://www.polygene.ch/). Briefly, this knock-in
mousemodelwas generated by homologous recombination in electroporation-
transfected embryonic stem (ES) cells on exon 3 of the Stim1 gene, located on
chromosome 7, inserting the c.343A>Tmutation (corresponding to isoleucine
to phenylalanine substitution; I115F). The linearized targeting vector F118.3
TV, with a flippase recognition target (FRT)-flanked neomycin resistance
cassette, inserted in an unsuspicious region in intron 3 of Stim1, was used for
the electroporation. The integrity of the targeting vector was confirmed by
sequencing exonic regions and by restriction analysis. G418 selection was
used to maintain stable transfection, and the clones obtained were analyzed
and validated by PCR and Southern blotting using BstEII-digested DNA
(internal probe) and a 3′ external probe (LA probe).
The selected ES clones were injected into 49 blastocysts from gray
C57Bl/6N mice. Forty-one surviving blastocysts were transferred to two
CD-1 foster mice. Resulting chimeras were mated to gray Flp-deleter mice.
The offspring from the chimeras were screened for the Flp-mediated
deletion of the neomycin cassette and the corresponding presence of the
remaining FRT site.
Mice were identified with the ear punch method at weaning and the piece
of tissue obtained was used to perform genotyping using a PCRBIO Rapid
Extract PCR Kit (PCR Biosystems, UK). DNA extraction was performed
according to the manufacturer’s instructions (5× PCRBIO Rapid Extract
Buffer A, 10× PCRBIO Rapid Extract Buffer B). For tissue lysis, the
samples were incubated at 75°C for 5 min. Another incubation at 95°C for
10 min was performed to deactivate proteases. Subsequently, the reaction
was stopped by adding mQ H2O, and centrifugation at 13,000 g for 1 min
was performed to eliminate the debris. The PCR reaction was conducted
using the following primers: FW, 5′-CCAGCAACTGAGGCATTC-3′;
REV, 5′-AAGAGGTGGAGTAGGCAGAG-3′. A single band was
obtained as a final PCR product in WT mice (617 bp), whereas a double
band was obtained in heterozygotes KI-STIM1I115F (617 bp and 746 bp),
related to the presence of the remaining FRT site.
Bleeding time
From an isoflurane-anesthetized animal, a segment of 2 mm was cut from
the tail tip and immersed in a solution of 0.9% NaCl (Sigma-Aldrich, Italy)
at 37°C. Bleeding time was measured for a maximum of 10 min to avoid
unnecessary suffering.
Behavioral tests
All behavioral tests were performed according to the Standard Operating
Protocols (SOPs) of the TREAT-NMD neuromuscular network (http://
www.treat-nmd.eu/research/preclinical/dmd-sops/).
Grip strength test
To measure the forelimb force in vivo, mice were suspended by the tail and
allowed to grasp on a rod. A force transducer, attached to the rod by the mice
grasp, was used to measure the force and the time of peak resistance. Five
trials per mouse were performed and data were normalized to mouse weight
(DMD_M.2.2.001). Experiments were performed in WT and KI-
STIM1I115F mice at 1, 2, 3, 4, 5, 6 and 12 months.
Hanging wire test
To determine ‘subacute’ muscle function and coordination, mice were
allowed to grasp onto the middle of a wire. Mice attempted to reach one of
the wire ends and the number of ‘falls’ or ‘reaches’ was recorded. From an
initial score of 10, each fall decreased the score by one and each reach
increased the score by 1. The experiment was terminated after 180 s or when
the animal reached zero as a score, whichever was earlier. A Kaplan–Meier-
like curve was created with all data obtained (DMD_M.2.1.004).
Experiments were performed in WT and KI-STIM1I115F mice at 1, 2, 3,
4, 5, 6 and 12 months.
Rotarod test
To assess motor coordination and balance, animals were placed on a rotarod
with fixed speed (2.8 m/min or 10 rpm). Experiments were terminated after
five falls or after 5 min, whichever was earlier. Before the test, micewere left
to acclimatize to the experimental room, and mice habituation to the rotarod
for 1 min at low speed was performed (ESLIM_010_001; Shiotsuki et al.,
2010).
Treadmill test
To assess the resistance and fatigue of mice, enforced running on a treadmill
with no inclination at a fixed speed (12 m/min) was performed. The
experiment was terminated after 30 min or after the fifth grid-stop,
whichever came earlier. An acclimation period of 15 min in the
experimental room was needed, and training for a maximum of 30 min
was performed the previous day. Following the SOPs, no electric shock was
used on the grid and it was substituted by a gentle touch of the tail, requiring
two experimenters for continuous supervision of this test
(DMD_M.2.1.003, DMD_M.2.1.001).
CK assay
Blood was collected from isoflurane-anesthetized mice by submandibular
vein puncture. Approximately 250 µl of blood was collected into heparin
tubes to obtain plasma by centrifuging samples at 1200 g for 10 min at room
temperature (RT). CK determination was performed according to the
manufacturer’s instructions using a standard spectrophotometric method
with enzyme-coupled assay reagent from Point Scientific (C7522-150).
Absorbance at 340 nm was measured every minute for 2 min at 37°C to
calculate enzyme activity. Duplicate measurements were performed on each
serum sample.
Histological analysis
Muscles were trimmed of tendons and adhering non-muscle tissue, mounted
in Killik embedding medium (Bio-optica, Italy), frozen in liquid nitrogen-
cooled isopentane and stored at −80°C.
For conventional histological techniques, 8- to 10-μm-thick cryostat
sections were stained with Hematoxylin-Eosin, Masson Trichrome and
modified Gomori Trichrome (GT), to reveal general muscle architecture and
myopathological features.
For ultrastructural studies, small muscle specimens were fixed with
glutaraldehyde (2%, pH 7.4), then fixed with osmium tetroxide (2%),
dehydrated and embedded in resin. Longitudinally oriented ultra-thin
sections were obtained at different depths from one to three small blocks,
and stained with uranyl acetate and lead citrate. Ultra-thin sections of
transversally oriented blocks were obtained for only the most significant
findings. The grids were observed using a Morgagni Fei electron
microscope (The Netherlands) and were photo-documented using a Mega
View II Camera (SYS Technologies).
For CSA distribution, muscle slices were fixed in 4% paraformaldehyde
(PFA), permeabilized with 0.2% Triton X-100 in 1% bovine serum albumin
(BSA) for 15 min and blocked with 4% BSA for 30 min. They were then
incubated for 1 h with anti-laminin antibody (1:200; Dako, Agilent
Technologies) and for a further 45 min with secondary antibody (1:400;
anti-rabbit Alexa Fluor 488, Thermo Fisher Scientific) at RT. Images were
acquired using a Leica CTR5500 B fluorescent microscope (Leica
Biosystems, Germany) with the Leica Application SuiteX 1.5 software.
CSA of the total muscle fibers was quantified with ImageJ software
(v1.49o). For myosin heavy chain studies, muscle slices were not fixed with
PFA and were stained with anti-laminin antibody (1:200; Dako, Agilent
Technologies), BA-D5, Myosin Heavy Chain Type I (IgG2b; 1:50), SC-71,
Myosin Heavy Chain Type IIA (IgG1; 1:500), BF-F3 and Myosin Heavy
Chain Type IIB (IgM; 1:5), all obtained from the Developmental Studies
Hybridoma Bank (Iowa City, IA, USA).
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Characterization of blood cell population
T cell, B cell, Treg cell, NK cell, monocyte and granulocyte determination
Blood cells were collected from the eye vein of anesthetized mice, and
splenocytes from the spleen after filtration through cell strainers (70 µm).
Ammonium-chloride-potassium lysing buffer was used for the lysis of red
blood cells. Blood cells were labeled for 15 min at 4°C with fluorochrome-
conjugated monoclonal antibodies: CD45-FITC BD Biosciences Clone
30-F11 (1:100), Ly6G BV421 BioLegend Clone 1A8 (1:500), Ly6C
BV605 BD Biosciences Clone AL-21 (1:500), CD3e BV786 BD
Biosciences Clone 5OOA2 (1:500), CD45R (B220) PE BD Biosciences
Clone RA3-6B2 (1:500) and CD11b PE-Cy7 eBioscience Clone M1/70
(1:500). Splenocytes were labeled for 15 min at 4°C with fluorochrome-
conjugated monoclonal antibodies: CD3 BV786 BD Biosciences
(1:500), CD11b BV510 BD Biosciences (1:500), CD49b PE eBioscience
(1:500), CD4 BV650 BD Biosciences (1:500), CD25 FITC BioLegend
(1:500) and Foxp3 PerCP-Cy5.5 eBioscience (1:100). Samples were
acquired with a BD LSRII Fortessa (BD Biosciences) and analyzed with
FlowJo software.
Number of platelets
To determine platelet number, 18 µl of blood extracted from the
submandibular vein was mixed with 2 µl acid citrate dextrose (Sigma-
Aldrich). Ten microliters of the mixture was then blended with 190 µl
NaNH3 (Sigma-Aldrich) for 5 min at RT to induce the lysis of red blood
cells. Then, 10 µl of this solution was diluted in 90 µl of phosphate-buffered
saline (PBS). Counts were performed in a Burker chamber on a microscope
with a 40× objective (Dhanjal et al., 2007).
Cell cultures
WT and KI-STIM1I115F primary myoblasts were obtained from the
following muscles: gastrocnemius, TA, quadriceps femoris, extensor
digitorum longus, soleus, biceps brachii and diaphragm. Each muscle was
placed in a 60-mm dish in PBS, removed from the tendon, separated
longitudinally and subsequently chopped into smaller pieces. The small
fragments were incubated with Pronase® (Protease, Streptomyces griseus,
Calbiochem®, 25 KU) for 1 h at 37°C with shaking and neutralized
with Dulbecco’s modified Eagle medium (DMEM, Sigma-Aldrich),
supplemented with 10% heat-inactivated fetal calf serum (Gibco, Italy),
50 mg/ml L-glutamine (Sigma-Aldrich), 10 U/ml penicillin and 100 mg/ml
streptomycin (Sigma-Aldrich), and 1% chicken embryo extract (Sigma-
Aldrich). Tissues were then chopped into smaller pieces and passed through
pipettes of 10 ml and 5 ml, and the supernatant obtained was filtered in a
40-µm strainer and centrifuged at RT for 10 min at 1200 rpm (235 g). The
pellets were re-suspended and myoblasts were plated in a 100-mm dish in
DMEM, supplemented with 10% heat-inactivated fetal bovine serum (FBS)
(Gibco), 50 mg/ml L-glutamine (Sigma-Aldrich), 10 U/ml penicillin and
100 mg/ml streptomycin (Sigma-Aldrich), and 1% chicken embryo extract
(Sigma-Aldrich) for 90 min at 37°C, in a 5%CO2 humidified atmosphere, to
separate cells from debris. Supernatants were then centrifuged and plated in
a 2% gelatine-treated 35-mm dish in DMEM (Sigma-Aldrich),
supplemented with 20% heat-inactivated FBS (Gibco), 10% horse serum
(Gibco), 50 mg/ml L-glutamine (Sigma-Aldrich), 10 U/ml penicillin and
100 mg/ml streptomycin (Sigma-Aldrich), 1% chicken embryo extract
(Sigma-Aldrich) and 10 ng/ml fibroblast growth factor (Peprotech, UK) at
37°C, in a 5% CO2 humidified atmosphere for 6-7 days, with a medium
change every 24-36 h.
For differentiation into myotubes, myoblasts were transferred for 48 h
into differentiation medium consisting of DMEM with 5% horse serum and
1% penicillin-streptomycin.
For calcium-imaging experiments, myotubes were further maintained in
the same medium for 24 h upon plating onto glass coverslips at a
concentration of 20×104 per well (24-mm diameter coverslips in 6-well
plates) and maintained in DMEM supplemented with 10% heat-inactivated
FBS (Gibco), 50 mg/ml L-glutamine (Sigma-Aldrich), and 10 U/ml
penicillin and 100 mg/ml streptomycin (Sigma-Aldrich), at 37°C in a 5%
CO2 humidified atmosphere. Experiments were performed 6-7 days after the
extraction at cell passage number (P)2 and P3.
Fura-2 Ca2+ experiments
Myotubes fromWT and KI-STIM1I115F mice were loaded with 5 µM Fura-2
AM in the presence of 0.02% Pluronic-127 (both from Life Technologies,
Italy) and 10 µM sulfinpyrazone (Sigma-Aldrich) in Krebs–Ringer buffer
(KRB; 135 mM NaCl, 5 mM KCl, 0.4 mM KH2PO4, 1 mM MgSO4,
5.5 mM glucose, 20 mMHEPES, pH 7.4) containing 2 mMCaCl2 (30 min,
RT). Then, cells were washed and incubated with KRB for 30 min to allow
the de-esterification of Fura-2.
To measure SOCE, changes in cytosolic Ca2+ were monitored upon
depletion of the intracellular Ca2+ stores. Experiments were carried out prior
to and during exposure of the cells to the Ca2+-free solution. In the absence
of Ca2+, the intracellular Ca2+ stores were depleted by inhibition of the
vesicular Ca2+ pump by tBHQ (50 µM; Sigma-Aldrich). Re-addition of
2 mM Ca2+ allowed assessment of the SOCE.
During the experiments, the coverslips were mounted into an acquisition
chamber and placed on the stage of a Leica DMI6000 epifluorescent
microscope equipped with S Fluor ×40/1.3 objective. Fura-2 was excited by
alternating 340 nm and 380 nm using a Polychrome IV monochromator
(Till Photonics, Germany), and the probe emission light was filtered through
a 520/20 bandpass filter and collected by a cooled CCD camera
(Hamamatsu, Japan). The fluorescence signals were acquired and
processed using MetaFluor software (Molecular Devices, USA). To
quantify the differences in the amplitudes of Ca2+ transients, the ratio
values were normalized using the formula ΔF/F0.
qRT-PCR
Total RNA from WT and KI-STIM1I115F myotubes was isolated using
TRI-Reagent® and reverse transcribed according to the manufacturer’s
instructions (Life Technologies). cDNA was then stored at −20°C until
further use. qRT-PCRs were performed on 96-well plates (CFX96™
Real-Time PCR Detection Systems, Bio-Rad, Italy), in triplicate, and
fluorescence intensity was assessed.
Primers used are listed in Table S1. Transcripts were normalized to the
expression of ribosomal protein S18 mRNAs; for each gene, the threshold
cycle (ΔCt) was calculated.
Statistical analysis
The normality of data distributions was assessed using Shapiro–Wilk test
and data are presented as mean±s.e.m. or median and interquartile range
(IQR), according to distribution. Parametric [unpaired Student’s t-test and
one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc] or
non-parametric (Mann–Whitney U-test and one-way Kruskal–Wallis H test
followed by Dunn’s post-hoc) statistical analyses were used. All statistical
assessments were two-sided and P<0.05 was considered statistically
significant. Statistical analyses were performed using Prism software
(GraphPad Software, USA). Statistical significance was tested between the
two mouse strains at the same age and was not tested for changes in time.
In calcium-imaging in vitro experiments, n represents the number of cells,
and the number of independent experiments (defined as experiments
performed on different days) is provided in the respective figure legends.
For in vivo experiments, n represents the number of animals studied.
In experiments involving histology, the figures shown are representative of
at least three experiments (histologic coloration), performed on different
experimental days on the tissue sections collected from all animals in
each group.
This article is part of a special collection ‘A Guide to Using Neuromuscular
Disease Models for Basic and Preclinical Studies’, which was launched in a
dedicated issue guest edited by Annemieke Aartsma-Rus, Maaike van Putten and
James Dowling. See related articles in this collection at http://dmm.biologists.org/
collection/neuromuscular.
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